Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity

NCT07590219 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Severe Obesity
Cardiovascular Function
Liraglutide
Childhood Obesity
Echocardiography
Speckle Tracking

Interventions

DRUG: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml

Sponsor

University of Sao Paulo General Hospital